Müllerian inhibiting substance type II receptor (MISIIR): A novel, tissue-specific target expressed by gynecologic cancers

Gynecologic Oncology

Volumn 108, Issue 1, 2008, Pages 141-148

  Bakkum Gamez, Jamie N ^a   Aletti, Giovanni ^a   Lewis, Kriste A ^a   Keeney, Gary L ^a   Thomas, Bijoy M ^a   Navarro Teulon, Isabelle ^b   Cliby, William A ^a  

^a MAYO CLINIC   (United States)

^b INSERM   (France)

Author keywords

Endometrial cancer; Epithelial ovarian cancer; M llerian inhibiting substance (MIS); M llerian inhibiting substance type II receptor (MISIIR); Ovarian dysgerminoma; Uterine sarcoma

Indexed keywords

MESSENGER RNA; MUELLERIAN INHIBITING FACTOR; MULLERIAN INHIBITING SUBSTANCE TYPE II RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER SURVIVAL; CHI SQUARE TEST; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG TARGETING; DYSGERMINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM SARCOMA; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; LEIOMYOSARCOMA; MIXED MULLERIAN TUMOR; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TISSUE SPECIFICITY; UTERUS MYOMA; UTERUS SARCOMA;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, PEPTIDE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSFECTION;

EID: 37449021993     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.09.010     Document Type: Article

References (29)

1. Masiakos P.T., et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) Type II receptor, bind, and are responsive to MIS. Clin Cancer Res 5 (1999) 3488-3499
2. Hoshiya Y., et al. Mullerian inhibiting substance promotes interferon {gamma}-induced gene expression and apoptosis in breast cancer cells. J Biol Chem 278 (2003) 51703-51712
3. Hoshiya Y., et al. Mullerian inhibiting substance induces NFkB signaling in breast and prostate cancer cells. Mol Cell Endocrinol 211 (2003) 43-49
4. Jemal A., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
5. Heintz A., Odicino F., and Maisonneuve P. Carcinoma of the ovary. J Epidemiol Biostat 6 (2001) 107
6. Kurian A.W., et al. Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynecol Oncol 96 (2005) 520-530
7. Hitoshi Okamura H.K., Nitta M., and Ohtake H. Structural changes and cell properties of human ovarian surface epithelium in ovarian pathophysiology. Microsc Res Tech 69 (2006) 469-481
8. Rey R., et al. AMH/MIS: what we know already about the gene, the protein and its regulation. Mol Cell Endocrinol 211 (2003) 21-31
9. He W.W., Gustafson M.L., and Hirobe S. Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family. Dev Dyn 196 (1993) 133-142
10. Lee M., et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 81 (1996) 571-576
11. Visser J.A. AMH signaling: from receptor to target gene. Mol Cell Endocrinol 211 (2003) 65-73
12. Belville C., et al. Role of type I receptors for anti-Mullerian hormone in the SMAT-1 Sertoli cell line. Oncogene 24 (2005) 4984-4992
13. Tran T.T., et al. Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-{kappa}B-dependent Smad-independent mechanism. Mol Endocrinol 20 (2006) 2382-2391
14. Catlin E.A., et al. Mullerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung. Endocrinology 138 (1997) 790-796
15. Renaud E.J., et al. Endometrial cancer is a receptor-mediated target for Mullerian inhibiting substance. PNAS 102 (2005) 111-116
16. Connolly D.C., et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 63 (2003) 1389-1397
17. Yuan Q.-a., et al. Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol Cancer Ther 5 (2006) 2096-2105
18. Fuller Jr. A.F., Budzik G.P., and Donahoe P.K. Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay. Gynecol Oncol 22 (1985) 135-148
19. Stephen A.E., et al. Highly purified Mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 8 (2002) 2640-2646
20. Pieretti-Vanmarcke R., et al. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS Type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res 12 (2006) 1593-1598
21. Pieretti-Vanmarcke R., et al. Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. PNAS 103 (2006) 17426-17431
22. Conover C.A., et al. Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res 238 (1998) 439-449
23. Kelemen L.E., et al. Multivitamin and alcohol intake and folate receptor {alpha} expression in ovarian cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 2168-2172
24. Mariani A., S.T., Katzmann J.A., Riehle D.L., Dowdy S.C., Keeney G.L., et al. HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature. Anticancer Res 25 (2005) 2921-2927
25. Chien J., et al. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 116 (2006) 1994-2004
26. GenBank, Homo sapiens anti-Mullerian hormone receptor, type II (AMHR2), mRNA, February 1, 2004.
27. Salhi I., C.-R.S., Lamarre I., Laune D., Molina F., Pugniere M., et al. The anti-Mullerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J 379 (2004) 785-793
28. Josso N., di Clemente N., and Gouedard L. Anti-Mullerian hormone and its receptors. Mol Cell Endocrinol 179 (2001) 25-32
29. Teixeira J., et al. Developmental expression of a candidate mullerian inhibiting substance type II receptor. Endocrinology 137 (1996) 160-165